YARDLEY, PA — Jubilant Therapeutics Inc. has appointed Daniel J. O’Connor as its new president and chief executive officer, effective December 1, 2025, marking a major leadership shift as the company advances its oncology pipeline.
O’Connor brings more than three decades of experience in biotechnology and cancer drug development. He most recently led Ambrx Biopharma, where he oversaw a sharp rise in company valuation ahead of its acquisition. His earlier tenure at ImClone Systems included key contributions to the development, launch, and commercialization of a leading oncology therapy while navigating complex intellectual property issues.
At Advaxis, a former NASDAQ-listed immuno-oncology firm, O’Connor expanded the organization into a late-stage clinical enterprise, secured significant growth capital, and structured partnerships with major pharmaceutical companies.
Hari S Bhartia, chairman of Jubilant Therapeutics Inc., said the company is “delighted to welcome Dan as CEO,” citing his track record in building biopharmaceutical platforms and advancing oncology-focused strategies.
O’Connor said he is honored to take on the role and emphasized the company’s commitment to developing therapies for hard-to-treat cancers. “I look forward to collaborating closely with our talented team to advance our mission and deliver meaningful value to patients, partners and stakeholders alike,” he said.
O’Connor holds a Juris Doctor from Penn State Dickinson Law and previously served as an officer in the U.S. Marine Corps.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.